Stocktoria
DBV Technologies S.A. DBVT
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2012-03-29
DBV Technologies S.A. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.6M | $4.2M | $15.7M | $4.8M | $5.7M | $11.3M | $14.7M |
| R&D expense | $116.7M | $89.3M | $60.2M | $75.5M | $70.3M | $101.6M | $115.1M |
| Operating income | -$147.1M | -$116.6M | -$76.4M | -$96.6M | -$98.6M | -$158.8M | -$171.0M |
| Income tax | $491,000 | $55,000 | $7,000 | $70,000 | -$381,000 | -$10,000 | $610,000 |
| Net income | -$146.9M | -$113.9M | -$72.7M | -$96.3M | -$97.8M | -$159.6M | -$172.0M |
| EPS (diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | — | — |
| Operating cash flow | -$121.2M | -$104.5M | -$79.7M | -$55.7M | -$108.2M | -$165.6M | -$148.3M |
| Free cash flow | -$121.7M | -$106.8M | -$80.3M | -$56.4M | -$109.2M | -$168.4M | -$153.9M |
| Cash & equivalents | $194.2M | $32.5M | $141.4M | $209.2M | $77.3M | $196.4M | $193.3M |
| Inventory | — | — | — | — | — | $0 | $2.3M |
| Total assets | $233.7M | $65.7M | $183.0M | $246.5M | $146.7M | $272.2M | $271.7M |
| Total liabilities | $64.9M | $38.3M | $42.8M | $52.1M | $47.4M | $66.8M | $78.5M |
| Shareholders' equity | $168.8M | $27.4M | $140.2M | $194.5M | $99.3M | $205.5M | $193.2M |
Growth · year-over-year · Revenue CAGR -14.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +35.8% | -73.6% | +224.7% | -15.1% | -49.4% | -23.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.